The purpose of this study is to determine whether or not ACT01 is effective and tolerable alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with facial and/or scalp keratosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
Therapeutics Clinical Research
San Diego, California, United States
Dermatology Specialists Research, LLC
Louisville, Kentucky, United States
Dermatology Consulting Services; Zoe Diana Draelos, MD
High Point, North Carolina, United States
Tennessee Clinical Research Center
Nashville, Tennessee, United States
Treatment Success at End of Study Visit
Treatment success at end of study visit defined as % of participants with 100% clearance of AK lesions
Time frame: up to Day 57
Irritation Score
Percentage of participants with moderate or severe overall irritation at end of treatment.
Time frame: up to Day 57
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.